文献速递炎症性肠病

炎症性肠病试验中的洗脱期:系统文献综述与建议解决方案

Washout Periods in Inflammatory Bowel Disease Trials: A Systematic Literature Review and Proposed Solutions.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-09-22

该系统文献综述旨在回顾溃疡性结肠炎(UC)和克罗恩病(CD)3期随机对照试验中,与先前先进疗法或免疫抑制剂相关的不同洗脱期,并提出潜在解决方案以改善未来试验设计和患者入组。炎症性肠病(IBD)包括UC和CD,尽管有许多有效药物,仍有大量患者1年时未达到临床缓解并一生中接受手术,存在重要未满足需求和治疗缺口;同时观察到招募率急剧下降,多种因素导致招募率低,包括研究药物与先前先进疗法之间较长的洗脱期。

要点

  • UC和CD的3期随机对照试验中,先前先进疗法或免疫抑制剂的洗脱期长短不一,是影响招募率的因素之一。
  • 尽管有效药物众多,仍有显著比例患者1年未达临床缓解且一生中需手术,存在治疗缺口。
  • 该综述提出潜在解决方案,以改善未来临床试验设计和患者入组。

核心结论

  • 该研究回顾了UC和CD的3期随机对照试验中先前先进疗法或免疫抑制剂的洗脱期,并提出潜在解决方案以改善未来试验设计和患者入组。

研究设计与样本

  • 系统文献综述,回顾UC和CD的3期随机对照试验中先前先进疗法或免疫抑制剂的洗脱期。

主要发现

  • 炎症性肠病包括UC和CD,疾病负担 substantial,许多患者1年时未达临床缓解并一生中接受手术。
  • 多项随机对照试验正在进行或计划中,以开发更有效和耐受性更好的疗法。
  • 同时观察到招募率急剧下降,多种因素导致招募率低,包括研究药物与先前先进疗法之间较长的洗脱期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inflammatory bowel diseases (IBD), encompassing ulcerative colitis (UC) and Crohn's disease (CD), impose a substantial burden. Despite many effective molecules, significant numbers of patients do not achieve clinical remission at 1 year1 and undergo surgery during their lives, revealing an important unmet need and therapeutic gap. Multiple randomized controlled trials (RCTs) are ongoing or planned to develop more effective and tolerable therapies. In parallel, a dramatic decline in recruitment rates has been observed. A multitude of factors have contributed to poor recruitment rates, including a long washout period between the investigational drug and prior advanced therapies (ie, biologic or small molecule drug).2,3 This study aims to review the different washout periods with prior advanced therapies or immunosuppressants in phase 3 RCTs for UC and CD and to propose potential solutions to ultimately improve the design of clinical studies and patient enrollment in future trials.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Wils P, Jairath V, Sands BE, et al. Washout Periods in Inflammatory Bowel Disease Trials: A Systematic Literature Review and Proposed Solutions. Clin Gastroenterol Hepatol. 2023. PMID: 37743039. doi:10.1016/j.cgh.2023.09.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。